Curcumin
别名: Diferuloylmethane, Natural Yellow 3, Turmeric yellow 中文名称：姜黄素
Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow)是流行的印度香料姜黄的主要姜黄色素，属于姜科（Zingiberaceae）。它是p300 histone acetylatransferase（IC50~25 μM）和Histone deacetylase (HDAC)的抑制剂，能够激活Nrf2 pathway并抑制NF-κB的激活。Curcumin 可诱导线粒体自噬、细胞自噬、凋亡和细胞周期阻滞，并具有抗肿瘤的活性。Curcumin 可通过减少铁死亡介导的细胞死亡来减少横纹肌溶解相关的肾衰竭。Curcumin 对各种人类病原体（如流感病毒，丙型肝炎病毒，HIV等）具有抗感染特性。
Curcumin Chemical Structure
CAS: 458-37-7
产品质控
批次：
纯度：
99.94%
99.94
Curcumin相关产品
| 相关靶点 | HAT MYST GNAT p300/CBP | 点击展开 |
|---|---|---|
| 相关产品 | C646 Anacardic Acid MG149 A-485 WM-1119 YF-2 CPTH2 | 点击展开 |
| 相关化合物库 | 激酶抑制剂库 FDA药物库 天然产物库 已知活性药物库-I 高选择性抑制剂库 | 点击展开 |
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| UMUC3 | Cell viability assay | 0.1 or 0.4 μg/ml | 24, 48, and 73 h | Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.5 μg/ml, each compared to respective controls | 30984278 |
| RT112 | Cell viability assay | 0.1 or 0.4 μg/ml | 24, 48, and 72 h | Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.4 μg/ml, each compared to respective controls | 30984278 |
| U87 | Cell viability assay | 0, 10, 20, 30, 40, and 50 µM/L | 24 hours | At concentrations higher than 20 µM/L, cell viabilities steeply declined | 31062527 |
| HEL cells | Cell viability assay | 0-30 µmol/L | 24/48 hours | The viability of the HEL cells exposed to curcumin was significantly lower compared to control cells even at low concentrations. | 31033209 |
| TCCSUP | Cell viability assay | 0.1 or 0.4 μg/ml | 24, 48, and 74 h | Curcumin alone, added at a concentration from 0.1 to 0.4 μg/ml, did not alter cell growth of RT112 cells, slightly reduced UMUC3 cell growth at 0.4 μg/ml, and only moderately suppressed growth of TCCSUP at 0.2 and 0.6 μg/ml, each compared to respective controls | 30984278 |
| A549 | Apoptosis assay | 2.1 to 4.2 uM | 24 hrs | Induction of apoptosis in human A549 cells at 2.1 to 4.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry | 26891099 |
| A549/CDDP | Apoptosis assay | 0.6 to 1.2 uM | 24 hrs | Induction of apoptosis in human A549/CDDP cells at 0.6 to 1.2 uM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometry | 26891099 |
| SH-SY5Y | Function assay | 1 to 5 uM | 24 hrs | Antioxidant activity against t-BHP-induced oxidative stress in human SH-SY5Y cells assessed as inhibition of ROS production at 1 to 5 uM after 24 hrs by DCFH-DA probe based flow cytometric analysis | 27856236 |
| K562 | Function assay | 20 to 30 uM | 48 hrs | Down regulation of p-gp expression in doxorubicin resistant human K562 cells at 20 to 30 uM measured after 48 hrs by Western blot method | 27908756 |
| K562 | Cell cycle assay | 20 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G0/G1 phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 |
| K562 | Cell cycle assay | 20 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as increase in G2/M phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 |
| K562 | Function assay | 20 to 40 uM | 48 hrs | Up regulation of p53 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 |
| K562 | Cell cycle assay | 20 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in S phase at 20 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 |
| K562 | Cell cycle assay | 30 to 40 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as accumulation at G0/G1 phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 |
| K562 | Cell cycle assay | 30 to 40 uM | 48 hrs | Cell cycle arrest in doxorubicin resistant human K562 cells assessed as decrease in G2/M phase at 30 to 40 uM measured after 48 hrs by propidium iodide staining based flow cytometry | 27908756 |
| K562 | Function assay | 20 to 40 uM | 48 hrs | Down regulation of cyclin B1 expression in doxorubicin resistant human K562 cells at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 |
| K562 | Apoptosis assay | 20 to 40 uM | 48 hrs | Induction of apoptosis in doxorubicin resistant human K562 cells decrease in pro-caspase 3 level at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 |
| K562 | Apoptosis assay | 20 to 40 uM | 48 hrs | Induction of apoptosis in doxorubicin resistant human K562 cells assessed as increase in PARP-1 cleavage at 20 to 40 uM measured after 48 hrs by Western blot method | 27908756 |
| PC12 | Neuroprotective assay | 0.1 to 10 uM | 24 hrs | Neuroprotective activity against H202-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay | 28302511 |
| PC12 | Neuroprotective assay | 0.1 to 10 uM | 24 hrs | Neuroprotective activity against Abeta42-induced toxicity in rat PC12 cells assessed as increase in cell viability at 0.1 to 10 uM after 24 hrs by MTT assay | 28302511 |
| cells at | Growth inhibition assay | 30 uM | 48 hrs | Growth inhibition of human Hep3B cells at 30 uM after 48 hrs by MTT assay | 28342400 |
| HepG2 | Function assay | 5 uM | 24 hrs | Activation of Nrf2 in human HepG2 cells assessed as cytoprotection against t-BHP-induced oxidative cell death at 5 uM incubated for 24 hrs followed by compound removal with subsequent incubation with 900 uM of t-BHP for 6 hrs by MTT assay | 28399452 |
| HCT116 | Function assay | 500 uM | 48 hrs | Induction of glutathione oxidation in human HCT116 cells assessed as increase in GSSG/GSH ratio at 500 uM in presence of NADPH after 48 hrs by Ellman's method | 28716495 |
| BGC823 | Growth inhibition assay | 20 uM | 72 hrs | Growth inhibition of human BGC823 cells at 20 uM after 72 hrs by MTT assay | 28881286 |
| SGC7901 | Growth inhibition assay | 20 uM | 72 hrs | Growth inhibition of human SGC7901 cells at 20 uM after 72 hrs by MTT assay | 28881286 |
| MFC | Growth inhibition assay | 20 uM | 72 hrs | Growth inhibition of MFC cells at 20 uM after 72 hrs by MTT assay | 28881286 |
| NCI-H460 | Growth inhibition assay | 5 to 10 uM | 24 to 72 hrs | Growth inhibition of human NCI-H460 cells assessed as reduction in cell viability at 5 to 10 uM incubated for 24 to 72 hrs by MTT assay | 29288946 |
| NCI-H460 | Growth inhibition assay | 20 uM | 18 hrs | Anti-growth activity against human NCI-H460 cells assessed as reduction in colony formation at 20 uM after 18 hrs by crystal violet-based colony forming assay | 29288946 |
| NCI-H460 | Antimigratory assay | 20 uM | 48 hrs | Anti-migratory activity against human NCI-H460 cells at 20 uM incubated for 48 hrs by wound healing assay | 29288946 |
| NCI-H460 | Apoptosis assay | 15 mg/kg | 15 days | Induction of apoptosis in tumor of human NCI-H460 cells xenografted in BALB/C nu nude mouse assessed as downregulation of bcl2 expression at 15 mg/kg, ip administered everyday for 15 days by Western blot analysis | 29288946 |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced apoptosis in mouse HT22 cells assessed as decrease in Bax/Bcl2 ratio at 1 uM after 24 hrs by RT-PCR method | 30031653 |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced oxidative stress in mouse HT22 cells assessed as decrease in iNOS mRNA level at 1 uM after 24 hrs by RT-PCR method | 30031653 |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell viability at 1 uM after 24 hrs by optical microscopic assay | 30031653 |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as decrease in glutamate-induced cell cycle arrest at sub-G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometry | 30031653 |
| HT22 | Cytoprotection assay | 1 uM | 24 hrs | Cytoprotection against glutamate-induced excitotoxicity in mouse HT22 cells assessed as increase in cell proliferation at 1 uM after 24 hrs by MTT assay | 30031653 |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control | 30780088 |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of LPS-induced p38 MAPK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis | 30780088 |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of LPS-induced ERK phosphorylation in ICR mouse RAW264.7 cells at 10 uM preincubated for 0.5 hrs followed by LPS challenge and measured after 30 mins by immunoblotting analysis | 30780088 |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of NFkappaB/MAPK signaling in LPS-induced mouse RAW264.7 cells assessed as down regulation of IkappaB expression at 10 uM preincubated for 0.5 hrs followed by LPS-challenge and measured after 30 mins by immunoblotting analysis | 30780088 |
| RAW264.7 | Function assay | 10 uM | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production at 10 uM pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA relative to control | 30780088 |
| Raw246.7 | Cell viability assay | 1, 5, 10, 50, 100, 200, and 500 g/mL | 31007701 | ||
| RAW264.7 | Antiinflammatory assay | 20 uM | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production at 20 uM by ELISA | 28284806 | |
| RAW264.7 | Antiinflammatory assay | 20 uM | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 20 uM by ELISA | 28284806 | |
| 3T3L1 | Function assay | 10 ng/ml | Inhibition of TNFalpha-induced NFkappaB activation (unknown origin) expressed in mouse 3T3L1 cells at 10 ng/ml by luciferase reporter gene assay | ChEMBL | |
| KBM5 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay, IC50 = 3.84 μM. | 24280069 | |
| Jurkat | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay, IC50 = 4.29 μM. | 24280069 | |
| U266 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human U266 cells after 72 hrs by MTT assay, IC50 = 7.57 μM. | 24280069 | |
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.3 μM. | 24280069 | |
| MCF7 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay, IC50 = 32.2 μM. | 26174555 | |
| SKOV3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay, IC50 = 43.63 μM. | 26174555 | |
| CT26 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 7.7 μM. | 26318057 | |
| SW620 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 12.52 μM. | 26318057 | |
| SGC7901 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 24.41 μM. | 26318057 | |
| GES-1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 27.89 μM. | 26318057 | |
| MGC803 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay, IC50 = 31.39 μM. | 26318057 | |
| U2OS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 22.8 μM. | 26606246 | |
| Saos2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 28.1 μM. | 26606246 | |
| U2OS | Cytotoxicity assay | 24 hrs | Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 34.4 μM. | 26606246 | |
| Saos2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay, EC50 = 48.6 μM. | 26606246 | |
| T98G | Antiproliferative assay | 24 hrs | Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay, IC50 = 10 μM. | 26631318 | |
| T98G | Antiproliferative assay | 72 hrs | Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay, IC50 = 25 μM. | 26631318 | |
| SH-SY5Y | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs, IC50 = 16.1 μM. | 26705144 | |
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs, IC50 = 21.8 μM. | 26705144 | |
| HeLa | Cell cycle assay | 16 hrs | Cell cycle arrest in human HeLa cells assessed as accumulation at G1 phase at IC50 to 2 times IC50 after 16 hrs by FACS analysis | 26705144 | |
| HuH7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay, IC50 = 48 μM. | 26783179 | |
| HeLa | Antiproliferative assay | 3 days | Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 12.11 μM. | 26827161 | |
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 13.61 μM. | 26827161 | |
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 25.43 μM. | 26827161 | |
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay, IC50 = 26.23 μM. | 26827161 | |
| RAW264.7 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 19.1 μM. | 26841168 | |
| BV2 | Function assay | 24 hrs | Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method, IC50 = 0.52 μM. | 26859776 | |
| A549/CDDP | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay, IC50 = 32.39 μM. | 26891099 | |
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 38.12 μM. | 26891099 | |
| bone marrow | Function assay | 48 hrs | Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay, IC50 = 7.5 μM. | 26923696 | |
| U937 | Function assay | 17 to 20 hrs | Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 1.88 μM. | 27040659 | |
| RAW264.7 | Function assay | 17 to 20 hrs | Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay, IC50 = 15.95 μM. | 27040659 | |
| BV2 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50 = 4.77 μM. | 27228227 | |
| SH-SY5Y | Neuroprotective assay | 24 hrs | Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay, EC50 = 6.2 μM. | 27420919 | |
| PC3 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 39 μM. | 27496212 | |
| DU145 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 41 μM. | 27496212 | |
| 4T1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay, IC50 = 49.4 μM. | 27496212 | |
| T47D | Cytotoxicity assay | 24 hrs | Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 30 μM. | 27517806 | |
| CHOK1 | Growth inhibition assay | 72 hrs | Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay, IC50 = 7.5 μM. | 27521589 | |
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay, IC50 = 13.61 μM. | 27543391 | |
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay, IC50 = 25.43 μM. | 27543391 | |
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay, IC50 = 26.23 μM. | 27543391 | |
| BV2 | Function assay | 1 hr | Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay, IC50 = 1.42 μM. | 27592135 | |
| BV2 | Function assay | 1 hr | Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay, IC50 = 2.2 μM. | 27617803 | |
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 15.06 μM. | 27816267 | |
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 24.54 μM. | 27816267 | |
| DU145 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 44.71 μM. | 27816267 | |
| EAhy926 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 24.6 μM. | 27843113 | |
| Caco2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 38.3 μM. | 27843113 | |
| CHOK1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 42 μM. | 27843113 | |
| NCI-H1650 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay, IC50 = 20.7 μM. | 27886548 | |
| LLC | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay, IC50 = 24.7 μM. | 27886548 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay, IC50 = 27.8 μM. | 27886548 | |
| K562 | Function assay | 48 hrs | Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay, GI50 = 19.67 μM. | 27908756 | |
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay, GI50 = 21.67 μM. | 27908756 | |
| H460 | Function assay | 48 hrs | Inhibition of P-gp in drug resistant human H460 cells assessed as reduction in cell viability measured after 48 hrs by sulforhodamine B assay, GI50 = 26 μM. | 27908756 | |
| NCI-H460 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay, GI50 = 27.3 μM. | 27908756 | |
| Raji | Function assay | 48 hrs | Inhibition of TPA-induced EBV-early antigen activation in human Raji cells after 48 hrs by indirect immunofluorescence method, IC50 = 12.1 μM. | 27933896 | |
| BV2 | Function assay | 24 hrs | Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 2.36 μM. | 28032759 | |
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 12.22 μM. | 28038323 | |
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 15.81 μM. | 28038323 | |
| BT549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 24.93 μM. | 28038323 | |
| HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay, IC50 = 25.41 μM. | 28038323 | |
| DU145 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 28.41 μM. | 28038323 | |
| BV2 | Function assay | 30 mins | Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay, IC50 = 4.5 μM. | 28055210 | |
| THP1 | Function assay | 1 hr | Inhibition of LPS-induced tissue factor procoagulant activity in human THP1 cells preincubated for 1 hr followed by LPS addition measured after 5 hrs using factor 10a chromogenic substrate in presence of prothrombin complex, IC50 = 0.01316 μM. | 28109788 | |
| BT474 | Antiproliferative assay | 24 hrs | Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay, IC50 = 30.14 μM. | 28319780 | |
| MDA-MB-453 | Antiproliferative assay | 24 hrs | Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay, IC50 = 32.4 μM. | 28319780 | |
| MDA-MB-157 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay, IC50 = 40.38 μM. | 28319780 | |
| SKBR3 | Antiproliferative assay | 24 hrs | Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay, IC50 = 42.83 μM. | 28319780 | |
| MCF7 | Antiproliferative assay | 24 hrs | Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay, IC50 = 42.89 μM. | 28319780 | |
| MDA-MB-468 | Antiproliferative assay | 24 hrs | Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay, IC50 = 42.89 μM. | 28319780 | |
| T47D | Antiproliferative assay | 24 hrs | Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay, IC50 = 47.91 μM. | 28319780 | |
| PWR-1E | Antiproliferative assay | 3 days | Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay, IC50 = 8.14 μM. | 28388523 | |
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50 = 13.61 μM. | 28388523 | |
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay, IC50 = 25.43 μM. | 28388523 | |
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay, IC50 = 26.23 μM. | 28388523 | |
| BV2 | Antineuroinflammatory assay | 15 mins | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method, IC50 = 6 μM. | 28514148 | |
| L428 | Function assay | 2 hrs | Inhibition of NF-kappaB (unknown origin) expressed in human L428 cells after 2 hrs by luciferase reporter gene assay | 28526369 | |
| PWR-1E | Antiproliferative assay | 3 days | Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay, IC50 = 8.85 μM. | 28601720 | |
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM. | 28601720 | |
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM. | 28601720 | |
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM. | 28601720 | |
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 12 μM. | 28654265 | |
| HT-29 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 14 μM. | 28654265 | |
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM. | 28654265 | |
| LN229 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 15 μM. | 28654265 | |
| U87 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 16 μM. | 28654265 | |
| COLO201 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM. | 28654265 | |
| A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 18 μM. | 28654265 | |
| T47D | Cytotoxicity assay | 48 hrs | Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM. | 28654265 | |
| MML1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 19 μM. | 28654265 | |
| BxPC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 29 μM. | 28654265 | |
| SK-MEL-2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50 = 36 μM. | 28654265 | |
| HCT116 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay, GI50 = 3.5 μM. | 28716495 | |
| HCT116 | Function assay | 48 hrs | Induction of mitochondrial membrane potential loss in human HCT116 cells at antiproliferative GI50 after 48 hrs by JC-1 staining based fluorescence assay | 28716495 | |
| HCT116 | Function assay | 60 mins | Induction of mitochondrial superoxide generation in human HCT116 cells at antiproliferative GI50 after 60 mins by mitoSOX red-probe based fluorescence assay | 28716495 | |
| HCT116 | Function assay | 60 mins | Induction of reactive oxygen species generation in human HCT116 cells at antiproliferative GI50 after 60 mins by DCFH-DA probe based assay | 28716495 | |
| MCF7 | Function assay | 48 hrs | Modulation activity at ER in human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 48 μM. | 28797797 | |
| BV2 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay, IC50 = 4 μM. | 29035525 | |
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 17.14 μM. | 29174816 | |
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 18.71 μM. | 29174816 | |
| DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 33.12 μM. | 29174816 | |
| HepG2 | Function assay | 5 hrs | Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay, EC50 = 21 μM. | 29223100 | |
| BGC823 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 19.5 μM. | 29288946 | |
| NCI-H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 20.3 μM. | 29288946 | |
| SGC7901 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 26.2 μM. | 29288946 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 13.78 μM. | 29421568 | |
| THP1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.54 μM. | 29421568 | |
| K562 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.12 μM. | 29421568 | |
| LO2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 25.67 μM. | 29421568 | |
| HeLa | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 31.89 μM. | 29421568 | |
| NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 17.11 μM. | 29429834 | |
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 18.65 μM. | 29429834 | |
| DU145 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50 = 33.15 μM. | 29429834 | |
| MCF7 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 22.1 μM. | 29605808 | |
| WRL68 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 27.8 μM. | 29605808 | |
| A549 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay, IC50 = 43.9 μM. | 29605808 | |
| NCI-H1975 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 1.4 μM. | 29655083 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 6.8 μM. | 29655083 | |
| HL7702 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 7.2 μM. | 29655083 | |
| H460 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 8.5 μM. | 29655083 | |
| NCI-H1650 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 20.5 μM. | 29655083 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 10 μM. | 29798827 | |
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay, IC50 = 10.91 μM. | 29886021 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 16.01 μM. | 29909338 | |
| SMMC7721 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 19.47 μM. | 29909338 | |
| QGY7703 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 21.44 μM. | 29909338 | |
| HHL5 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HHL5 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 22.27 μM. | 29909338 | |
| LO2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay, IC50 = 23.87 μM. | 29909338 | |
| HT22 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse HT22 cells assessed as reduction in cell viability after 24 hrs by MTT assay, MNTD = 1 μM. | 30031653 | |
| LNCAP | Antiproliferative assay | 3 days | Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 13.61 μM. | 30121214 | |
| PC3 | Antiproliferative assay | 3 days | Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 25.43 μM. | 30121214 | |
| DU145 | Antiproliferative assay | 3 days | Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay, IC50 = 26.23 μM. | 30121214 | |
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.8 μM. | 30138803 | |
| EJ28 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EJ28 cells after 72 hrs by MTT assay, IC50 = 10.5 μM. | 30138803 | |
| HT1080 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay, IC50 = 13.1 μM. | 30138803 | |
| SW620 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SW620 cells after 72 hrs by MTT assay, IC50 = 14 μM. | 30138803 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 17.9 μM. | 30138803 | |
| SMMC7721 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 16.68 μM. | 30771605 | |
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 17.37 μM. | 30771605 | |
| LO2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 22.69 μM. | 30771605 | |
| QGY7703 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 23.91 μM. | 30771605 | |
| HHL5 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HHL5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay, IC50 = 24.19 μM. | 30771605 | |
| HCT-116 | Function assay | 24 hrs | Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr, IC50 = 10 μM. | 30776692 | |
| SW480 | Function assay | 24 hrs | Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric, IC50 = 10 μM. | 30776692 | |
| RAW264.7 | Function assay | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced TNFalpha production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA | 30780088 | |
| RAW264.7 | Function assay | 0.5 hrs | Inhibition of LPS-induced NFkappaB p65 nuclear translocation in ICR mouse RAW264.7 cells preincubated for 0.5 hrs followed by LPS challenge and measured after 40 mins by DAPI staining-based immunofluorescence microscopic analysis | 30780088 | |
| RAW264.7 | Function assay | 0.5 hrs | Inhibition of MAPK/NFkappaB in ICR mouse RAW264.7 cells assessed as reduction in LPS-induced IL6 production pretreated for 0.5 hrs followed by LPS challenge and measured after 24 hrs by ELISA | 30780088 | |
| RAW264.7 | Function assay | 4 hrs | Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs, IC50 = 3 μM. | 30794412 | |
| BV2 | Antineuroinflammatory assay | 1 hr | Anti-neuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess reagent based assay, IC50 = 1.58 μM. | 31005056 | |
| SKOV3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay, IC50 = 6.7 μM. | 31129455 | |
| U87MG | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U87MG Cells 48 hrs by MTS assay, IC50 = 7.15 μM. | 31129455 | |
| LX2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LX2 Cells after 48 hrs by MTT assay, IC50 = 9.14 μM. | 31129455 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay, IC50 = 9.28 μM. | 31129455 | |
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay, IC50 = 9.44 μM. | 31129455 | |
| 3T3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay, IC50 = 9.51 μM. | 31129455 | |
| MDA-MB-231 | Anticancer assay | 72 hrs | Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 11.45 μM. | 31129455 | |
| SMMC7721 | Anticancer assay | 72 hrs | Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50 = 12.57 μM. | 31129455 | |
| LX2 | Anticancer assay | 72 hrs | Anticancer activity against human LX2 cells after 72 hrs by MTT assay, IC50 = 13.97 μM. | 31129455 | |
| SW480 | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay, IC50 = 15 μM. | 31129455 | |
| U251MG | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U251MG cells after 48 hrs by MTS assay, IC50 = 15.26 μM. | 31129455 | |
| EAhy926 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay, IC50 = 20 μM. | 31129455 | |
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay, IC50 = 20.3 μM. | 31129455 | |
| CHOK1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay, IC50 = 21.3 μM. | 31129455 | |
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay, IC50 = 23.4 μM. | 31129455 | |
| A549 | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay, IC50 = 28 μM. | 31129455 | |
| Caco2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay, IC50 = 28 μM. | 31129455 | |
| MDCK2 | Cytotoxicity assay | 15 mins | Cytotoxicity against mitoxantrone resistant human MDCK2 cells expressing BCRP after 15 mins by fluorescence assay, IC50 = 32 μM. | 31129455 | |
| K562 | Cytotoxicity assay | 24 to 48 hrs | Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay, IC50 = 36 μM. | 31129455 | |
| GBM1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human GBM1 Cells 48 hrs by MTS assay, IC50 = 39.65 μM. | 31129455 | |
| PC12 | Cytotoxicity assay | 24 hrs | Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay, CC50 = 42 μM. | 31262559 | |
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 10.5 μM. | 31326241 | |
| KM12 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human KM12 cells after 4 hrs by MTT assay, IC50 = 16 μM. | 31336310 | |
| SW480 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human SW480 cells after 4 hrs by MTT assay, IC50 = 17.94 μM. | 31336310 | |
| HT-29 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay, IC50 = 20.73 μM. | 31336310 | |
| WiDr | Cytotoxicity assay | 4 hrs | Cytotoxicity against human WiDr cells after 4 hrs by MTT assay, IC50 = 26.82 μM. | 31336310 | |
| SW116 | Cytotoxicity assay | 4 hrs | Cytotoxicity against human SW116 cells after 4 hrs by MTT assay, IC50 = 27.46 μM. | 31336310 | |
| Colon 26 | Cytotoxicity assay | 4 hrs | Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay, IC50 = 30.34 μM. | 31336310 | |
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity human PC3 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay | 31767266 | |
| 22Rv1 | Antiproliferative assay | 48 hrs | Antiproliferative activity human 22Rv1 cells assessed as reduction in Ki67 protein level at GI50 incubated for 48 hrs by DAPI staining based immunofluorescence assay | 31767266 | |
| Sf21 | Function assay | 10 mins | Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co, IC50 = 25 μM. | 31910017 | |
| COS7 | Function assay | 10 mins | Inhibition of rabbit SERCA1b expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 5.8 μM. | 32030976 | |
| COS7 | Function assay | 10 mins | Inhibition of human SERCA3a expressed in COS7 cells microsomal membranes preincubated for 10 mins followed by addition of ATP and measured after 40 mins by ELISA method, Ki = 8.6 μM. | 32030976 | |
| A549 | Function assay | 15 mins | Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis, IC50 = 0.2 μM. | ChEMBL | |
| RAW264.7 | Function assay | 20 hrs | Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay, IC50 = 0.8 μM. | ChEMBL | |
| MDCK | Antiviral assay | 40 hrs | Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM. | ChEMBL | |
| MDCK | Antiviral assay | 40 hrs | Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 40 hrs by CellTiter-Glo assay, IC50 = 6.7 μM. | ChEMBL | |
| RAW264.7 | Antiinflammatory assay | 17 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay, IC50 = 14.7 μM. | ChEMBL | |
| MDCK | Cytotoxicity assay | 40 hrs | Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM. | ChEMBL | |
| MDCK | Cytotoxicity assay | 40 hrs | Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay, CC50 = 48.3 μM. | ChEMBL | |
| Caco2 | Antiproliferative assay | Antiproliferative activity against human Caco2 cells, IC50 = 10.3 μM. | 26539626 | ||
| T67 | Neuroprotective assay | Neuroprotective effect in human T67 cells assessed as increase in NQO1 activity using DCIP as substrate | 26696252 | ||
| HepG2 | Cytotoxicity assay | Cytotoxicity activity against human HepG2 cells by MTT assay, IC50 = 4.43 μM. | 26873414 | ||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 cells by MTT assay, IC50 = 23.54 μM. | 26873414 | ||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells by MTT assay, IC50 = 46.25 μM. | 26873414 | ||
| SKOV3 | Cytotoxicity assay | Cytotoxicity against human SKOV3 cells by MTT assay, IC50 = 49.85 μM. | 26873414 | ||
| A549/CDDP | Function assay | Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry, IC50 = 39.42 μM. | 26891099 | ||
| A549 | Function assay | Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry, IC50 = 40.56 μM. | 26891099 | ||
| HCT116 | Antiproliferative assay | Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay, IC50 = 13.77 μM. | 28319780 | ||
| MDA-MB-231 | Antiproliferative assay | Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay, IC50 = 16.23 μM. | 28319780 | ||
| PC3 | Antiproliferative assay | Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay, IC50 = 18.8 μM. | 28319780 | ||
| A549 | Growth inhibition assay | Growth inhibition of human A549 cells, IC50 = 23 μM. | 28814374 | ||
| Vero | Cytotoxicity assay | Cytotoxicity against African green monkey Vero cells assessed as growth inhibition, CC50 = 36.8 μM. | 29920454 | ||
| LNCAP | Antiproliferative assay | Antiproliferative activity against androgen-sensitive human LNCAP cells, IC50 = 2 μM. | 30121214 | ||
| DU145 | Antiproliferative assay | Antiproliferative activity against androgen-insensitive human DU145 cells, IC50 = 2 μM. | 30121214 | ||
| PC3 | Antiproliferative assay | Antiproliferative activity against androgen-insensitive human PC3 cells, IC50 = 2 μM. | 30121214 | ||
| HeLa | Anticancer assay | Anticancer activity against human HeLa cells, IC50 = 4.33 μM. | 31129455 | ||
| HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells, IC50 = 6.3 μM. | 31129455 | ||
| HSC4 | Cytotoxicity assay | Cytotoxicity against human HSC4 cells, IC50 = 7.1 μM. | 31129455 | ||
| HSC2 | Cytotoxicity assay | Cytotoxicity against human HSC2 cells, IC50 = 7.8 μM. | 31129455 | ||
| AGS | Cytotoxicity assay | Cytotoxicity against human AGS Cells, IC50 = 9.77 μM. | 31129455 | ||
| HSC3 | Cytotoxicity assay | Cytotoxicity against human HSC3 cells, IC50 = 11 μM. | 31129455 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa Cells, IC50 = 14.03 μM. | 31129455 | ||
| RWPE1 | Cytotoxicity assay | Cytotoxicity against human RWPE1 cells, IC50 = 15.62 μM. | 31129455 | ||
| MCF7 | Apoptosis assay | Induction of apoptosis in human MCF7 cells, IC50 = 17.1 μM. | 31129455 | ||
| BGC823 | Cytotoxicity assay | Cytotoxicity against human BGC823 cells, IC50 = 17.5 μM. | 31129455 | ||
| BxPC3 | Cytotoxicity assay | Cytotoxicity against human BxPC3 cells, IC50 = 18.25 μM. | 31129455 | ||
| HT-29 | Cytotoxicity assay | Cytotoxicity against human HT-29 Cells, IC50 = 18.74 μM. | 31129455 | ||
| H1299 | Cytotoxicity assay | Cytotoxicity against human H1299 cells, IC50 = 18.93 μM. | 31129455 | ||
| PC3 | Cytotoxicity assay | Cytotoxicity against human PC3 cells, IC50 = 19.98 μM. | 31129455 | ||
| AGS | Cytotoxicity assay | Cytotoxicity against human AGS Cells by MTT assay, IC50 = 20.76 μM. | 31129455 | ||
| PC3 | Anticancer assay | Anticancer activity against human PC3 cells, IC50 = 20.9 μM. | 31129455 | ||
| MGC803 | Cytotoxicity assay | Cytotoxicity against human MGC803 cells, IC50 = 21.2 μM. | 31129455 | ||
| Hep2 | Cytotoxicity assay | Cytotoxicity against human Hep2 Cells, IC50 = 21.37 μM. | 31129455 | ||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells, IC50 = 22.5 μM. | 31129455 | ||
| SGC7901 | Cytotoxicity assay | Cytotoxicity against human SGC7901 cells, IC50 = 22.5 μM. | 31129455 | ||
| A549 | Cytotoxicity assay | Cytotoxicity against human A549 Cells by MTT assay, IC50 = 25.33 μM. | 31129455 | ||
| MDA-MB-231 | Cytotoxicity assay | Cytotoxicity against human MDA-MB-231 cells, IC50 = 26.5 μM. | 31129455 | ||
| GES-1 | Cytotoxicity assay | Cytotoxicity against human GES-1 cells, IC50 = 29.1 μM. | 31129455 | ||
| DU145 | Anticancer assay | Anticancer activity against human DU145 cells, IC50 = 31.7 μM. | 31129455 | ||
| HL-7702 | Cytotoxicity assay | Cytotoxicity against human HL-7702 cells, IC50 = 32.33 μM. | 31129455 | ||
| HepG2 | Cytotoxicity assay | Cytotoxicity against human HepG2 Cells, IC50 = 36.77 μM. | 31129455 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells, IC50 = 8.2 μM. | 31336310 | ||
| B16 | Cytotoxicity assay | Cytotoxicity against human B16 cells by MTT assay, IC50 = 8.5 μM. | 31336310 | ||
| HT1080 | Function assay | Decrease in UPA expression in human HT1080 cells, IC50 = 10 μM. | 31336310 | ||
| Hep3B | Cytotoxicity assay | Cytotoxicity against human Hep3B cells, IC50 = 10 μM. | 31336310 | ||
| BT474 | Cytotoxicity assay | Cytotoxicity against human BT474 cells, IC50 = 11 μM. | 31336310 | ||
| T47D | Cytotoxicity assay | Cytotoxicity against human T47D cells, IC50 = 11 μM. | 31336310 | ||
| HaCaT | Cytotoxicity assay | Cytotoxicity against human HaCaT cells, IC50 = 13 μM. | 31336310 | ||
| HPL1D | Cytotoxicity assay | Cytotoxicity against human HPL1D cells, IC50 = 16 μM. | 31336310 | ||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells, IC50 = 19.9 μM. | 31336310 | ||
| 22Rv1 | Function assay | Inhibition of NFkappaB p65 nuclear translocation in human 22Rv1 cells at GI50 by DAPI staining based immunofluorescence assay | 31767266 | ||
| PC3 | Function assay | Inhibition of NFkappaB p65 nuclear translocation in human PC3 cells at GI50 by DAPI staining based immunofluorescence assay | 31767266 | ||
| PC3 | Function assay | Inhibition of NFkappaB p65 transcriptional activity in human PC3 cells at GI50 by sandwich ELISA | 31767266 | ||
| 22Rv1 | Function assay | Inhibition of NFkappaB p65 transcriptional activity in human 22Rv1 cells at GI50 by sandwich ELISA | 31767266 | ||
| HEK293T | Cytotoxicity assay | Cytotoxicity against HEK293T cells, IC50 = 15.2 μM. | ChEMBL | ||
| J774.1 | Cytotoxicity assay | Cytotoxicity against mouse J774.1 cells, IC50 = 31 μM. | ChEMBL | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow)是流行的印度香料姜黄的主要姜黄色素，属于姜科（Zingiberaceae）。它是p300 histone acetylatransferase（IC50~25 μM）和Histone deacetylase (HDAC)的抑制剂，能够激活Nrf2 pathway并抑制NF-κB的激活。Curcumin 可诱导线粒体自噬、细胞自噬、凋亡和细胞周期阻滞，并具有抗肿瘤的活性。Curcumin 可通过减少铁死亡介导的细胞死亡来减少横纹肌溶解相关的肾衰竭。Curcumin 对各种人类病原体（如流感病毒，丙型肝炎病毒，HIV等）具有抗感染特性。 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06053411 | Not yet recruiting | Interaction |
Washington State University |
January 1 2024 | Early Phase 1 |
| NCT05947513 | Not yet recruiting | Cervical Cancer |
Addis Ababa University|Center for Innovative Drug Development and Therapeutic Trials for Africa Addis Ababa University|Akay Natural Ingredients Private Limited |
October 2023 | Phase 1|Phase 2 |
| NCT05966441 | Not yet recruiting | Chemotherapy-induced Peripheral Neuropathy |
Ain Shams University |
August 30 2023 | Phase 2 |
| NCT05774704 | Recruiting | Bioavailability|Gut Microbiome|Safety |
Texas Tech University Health Sciences Center |
August 21 2023 | Phase 1|Phase 2 |
化学信息&溶解度
| 分子量 | 368.38 | 分子式 | C21H20O6 |
| CAS号 | 458-37-7 | SDF | Download Curcumin SDF |
| Smiles | COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 74 mg/mL ( (200.87 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Curcumin | Curcumin ic50 | Curcumin price | Curcumin cost | Curcumin solubility dmso | Curcumin purchase | Curcumin manufacturer | Curcumin research buy | Curcumin order | Curcumin mouse | Curcumin chemical structure | Curcumin mw | Curcumin molecular weight | Curcumin datasheet | Curcumin supplier | Curcumin in vitro | Curcumin cell line | Curcumin concentration | Curcumin nmr
